WallStreetZenWallStreetZen

NASDAQ: VKTX
Viking Therapeutics Inc Stock

$9.10-0.09 (-0.98%)
Updated Feb 3, 2023
VKTX Price
$9.10
Fair Value Price
$9.48
Market Cap
$697.87M
52 Week Low
$2.02
52 Week High
$9.62
P/E
-11.23x
P/B
4.61x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$61.66M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.1
Operating Cash Flow
-$50M
Beta
1.17
Next Earnings
Feb 8, 2023
Ex-Dividend
N/A
Next Dividend
N/A

VKTX Overview

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VKTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VKTX ($9.10) is undervalued by 4.05% relative to our estimate of its Fair Value price of $9.48 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
VKTX ($9.10) is not significantly undervalued (4.05%) relative to our estimate of its Fair Value price of $9.48 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VKTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VKTX due diligence checks available for Premium users.

Be the first to know about important VKTX news, forecast changes, insider trades & much more!

VKTX News

Valuation

VKTX fair value

Fair Value of VKTX stock based on Discounted Cash Flow (DCF)
Price
$9.10
Fair Value
$9.48
Undervalued by
4.05%
VKTX ($9.10) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VKTX ($9.10) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VKTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VKTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-11.23x
Industry
10.7x
Market
15.09x

VKTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.61x
Industry
5.11x
VKTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VKTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$15.8M
Profit Margin
0%
VKTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$166.7M
Liabilities
$15.4M
Debt to equity
0.1
VKTX's short-term assets ($165.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VKTX's short-term assets ($165.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VKTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VKTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$13.5M
Investing
$26.9M
Financing
$10.0k
VKTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VKTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VKTX$697.87M-0.98%-11.23x4.61x
MRSN$700.41M+1.89%-2.89x7.76x
PTGX$705.01M-0.90%-5.35x2.89x
PSTX$690.17M+4.83%-11.81x3.19x
MCRB$685.25M-3.00%-2.34x10.14x

Viking Therapeutics Stock FAQ

What is Viking Therapeutics's quote symbol?

NASDAQ: VKTX) Viking Therapeutics trades on the NASDAQ under the ticker symbol VKTX. Viking Therapeutics stock quotes can also be displayed as NASDAQ: VKTX.

If you're new to stock investing, here's how to buy Viking Therapeutics stock.

What is the 52 week high and low for Viking Therapeutics (NASDAQ: VKTX)?

(NASDAQ: VKTX) Viking Therapeutics's 52-week high was $9.62, and its 52-week low was $2.02. It is currently -5.41% from its 52-week high and 350.5% from its 52-week low.

How much is Viking Therapeutics stock worth today?

(NASDAQ: VKTX) Viking Therapeutics currently has 76,688,478 outstanding shares. With Viking Therapeutics stock trading at $9.10 per share, the total value of Viking Therapeutics stock (market capitalization) is $697.87M.

Viking Therapeutics stock was originally listed at a price of $8.96 in Apr 29, 2015. If you had invested in Viking Therapeutics stock at $8.96, your return over the last 7 years would have been 1.56%, for an annualized return of 0.22% (not including any dividends or dividend reinvestments).

How much is Viking Therapeutics's stock price per share?

(NASDAQ: VKTX) Viking Therapeutics stock price per share is $9.10 today (as of Feb 3, 2023).

What is Viking Therapeutics's Market Cap?

(NASDAQ: VKTX) Viking Therapeutics's market cap is $697.87M, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Viking Therapeutics's market cap is calculated by multiplying VKTX's current stock price of $9.10 by VKTX's total outstanding shares of 76,688,478.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.